Ronald Pauls, PA
Physician Assistant · Seminole, OKNPI 1912182627
Payments from drug & device makers
Across 234 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$632
- AstraZeneca$381
- Amgen$337
- Novo Nordisk$243
- GSK$169
- plus $756 from 19 others
What the payments were for
- Food & beverage$3,664100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 74 | $1,145 |
| Lilly USA, LLC | 41 | $632 |
| AstraZeneca | 25 | $381 |
| Amgen | 22 | $337 |
| Novo Nordisk | 15 | $243 |
| GSK | 12 | $169 |
| Pfizer | 9 | $157 |
| Xeris Pharmaceuticals, Inc. | 4 | $78 |
| Sanofi-aventis U.S. LLC | 3 | $63 |
| Sumitomo Pharma America, Inc. | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Novartis | 4 | $53 |
| Amarin Pharma, Inc. | 3 | $51 |
| Organon | 3 | $48 |
| Exact Sciences | 2 | $30 |
| Merck | 2 | $29 |
| Boehringer Ingelheim | 1 | $19 |
| Insulet Corporation | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
How this compares
$3,664 in reported general payments places this provider in the 85th percentile of 1,491 physician assistant providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 128 | $168,944 |
| OzempicSemaglutide | 130 | $133,507 |
| FarxigaDapagliflozin Propanediol | 107 | $101,438 |
| JardianceEmpagliflozin | 81 | $74,361 |
| TrulicityDulaglutide | 64 | $73,071 |
| Tresiba Flextouch U-200Insulin Degludec | 52 | $52,735 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $43,183 |
| EliquisApixaban | 47 | $35,504 |
| Repatha SureclickEvolocumab | 47 | $25,424 |
| RexultiBrexpiprazole | 16 | $24,572 |
| VraylarCariprazine Hcl | 16 | $23,014 |
| LinzessLinaclotide | 23 | $19,148 |
| XareltoRivaroxaban | 21 | $18,727 |
| MyrbetriqMirabegron | 30 | $17,825 |
| JanuviaSitagliptin Phosphate | 16 | $16,446 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $632 | $242,014192 claims |
| Novo NordiskOzempic | $243 | $133,507130 claims |
| AstraZenecaFarxiga, Symbicort | $381 | $109,338131 claims |
| Boehringer IngelheimJardiance | $19 | $74,36181 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $169 | $49,26673 claims |
| AbbVieVraylar, Linzess | $1,145 | $42,16239 claims |
| PfizerEliquis, Premarin | $157 | $39,89460 claims |
| MerckJanuvia, Janumet, Belsomra | $29 | $31,44142 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $54 | $24,57216 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $17,82530 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $54 | $12,80021 claims |
| NovartisEntresto | $53 | $11,79118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,491 physician assistant providers in Oklahoma.
Other physician assistant in Seminole
- Eric CampbellEdmond$246K
- Katherine DemersEl Reno$146K
- Jennifer SmithOklahoma City$134K
- Christy NiehuesMustang$28K
- Matthew PattonTulsa$24K
- Sarah HawkOklahoma City$23K
- Gavin ChristieEdmond$19K
- Michelle GreenTulsa$18K
- Muge ParkTulsa$17K
- Rose RamirezTulsa$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.